The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?
详细信息 查看全文
- 作者：Lynn Unruha ; lynn.unruh@ucf.edu" class="auth_mail" title="E-mail the corresponding author ; Thomas Riceb ; 1 ; trice@ucla.edu" class="auth_mail" title="E-mail the corresponding author ; Pauline Vaillancourt Rosenauc ; 2 ; Pauline.Rosenau@uth.tmc.edu" class="auth_mail" title="E-mail the corresponding author ; Andrew J. Barnesd ; 3 ; Abarnes3@vcu.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Cardiovascular disease ; Cholesterol guidelines ; Clinical guidelines ; Conflict of interest ; Pharmaceuticalization ; Lifestyle changes
- 刊名：Health Policy
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：120
- 期：7
- 页码：797-808
- 全文大小：1378 K
文摘
- •
The 2013 U.S. cholesterol guideline recommends the use of statins for primary prevention of CVD in low risk individuals.
- •
This expands the number of patients for whom the use of statins is recommended.
- •
The recommendation has been controversial due to disagreement about the robustness of the evidence base.
- •
Pharma is involved in the development of clinical guidelines – from trial design to data analysis to meta-analysis of studies.
- •
Policies could reduce the influence of Pharma on the research process and prevent pharmaceuticalization.